Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

Slides:



Advertisements
Similar presentations
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Advertisements

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Women’s Health Study: Vitamin E in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Julie E. Buring.
Glucose – Insulin – Potassium Study in Patients with ST Elevation Myocardial Infarction without Signs of Heart Failure Presented at American College of.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
The overwhelming case for LDL-C lowering
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Continuous Positive Airway Pressure for Heart Patients with Central Sleep Apnea Presented at American College of Cardiology Scientific Sessions 2005 Presented.
Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.
Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
4S: Scandinavian Simvastatin Survival Study
Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Title slide.
The American College of Cardiology Presented by Dr. Steven E. Nissen
Pravastatin in Elderly Individuals at Risk of Vascular Disease
The American Heart Association Presented by Dr. Steven E. Nissen
TNT: Baseline and final LDL cholesterol levels
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
American College of Cardiology Presented by Dr. Stephan Windecker
This series of slides highlights a report based on a presentation at the Late-Breaking Trial Sessions of the 2005 American Heart Association Scientific.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
ARISE Trial Aggressive Reduction of Inflammation Stops Events
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
PROSPER: trial design                                                                                                                                                                 
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Presentation transcript:

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa

www. Clinical trial results.org Atorvastatin 80 mg n=4,995 Atorvastatin 80 mg n=4,995 Primary Endpoint: Major cardiovascular event defined as coronary heart death (CHD), nonfatal M, resuscitated cardiac arrest, and fatal or nonfatal stroke at a mean follow-up of 4.9 years. Secondary Endpoint: Major coronary events, cerebrovascular events, hospitalization for congestive heart failure (CHF), all-cause mortality, peripheral artery disease, any cardiovascular event, any coronary event Primary Endpoint: Major cardiovascular event defined as coronary heart death (CHD), nonfatal M, resuscitated cardiac arrest, and fatal or nonfatal stroke at a mean follow-up of 4.9 years. Secondary Endpoint: Major coronary events, cerebrovascular events, hospitalization for congestive heart failure (CHF), all-cause mortality, peripheral artery disease, any cardiovascular event, any coronary event TNT Trial Presented at ACC 2005 Atorvastatin 10 mg n=5,006 Atorvastatin 10 mg n=5,006 10,003 patients with stable coronary heart disease Age years, LDL between 130 and 250 mg/dL, triglyceride ≤ 600 mg/dL 19% female, mean age 60.3 years All received atorvastatin 10 mg during 8 week open-label run-in period 10,003 patients with stable coronary heart disease Age years, LDL between 130 and 250 mg/dL, triglyceride ≤ 600 mg/dL 19% female, mean age 60.3 years All received atorvastatin 10 mg during 8 week open-label run-in period

www. Clinical trial results.org TNT Trial: Primary endpoint The primary composite endpoint of CHD death, nonfatal MI, resuscitated cardiac arrest, and fatal or nonfatal stroke was lower in the high-dose atorvastatin 80 mg group at a mean follow-up of 4.9 years. Primary Composite of CHD death, nonfatal MI, resuscitated cardiac arrest, and fatal or nonfatal stroke Hazard Ratio [HR]=0.78 p<0.001 Presented at ACC 2005

www. Clinical trial results.org TNT Trial: Primary Endpoint p=0.09 p=0.004 p=0.89 p=0.02 The individual components of the primary endpoint were also lower or tended to be lower in the high-dose group compared to the low-dose group with the exception of resuscitation after cardiac arrest, which was the equal in both groups. Presented at ACC 2005

www. Clinical trial results.org TNT Trial: Secondary Endpoint The components of the secondary endpoint that were lower in the high-dose group included: major coronary events, cerebrovascular events, and hospitalization for CHF. All-cause mortality and peripheral artery disease were equivalent in both high and low dose groups. Cerebrovascular Events p=0.007 Major Coronary Events p=0.002 CHF p=0.01 All-cause Mortality p=0.92 Peripheral Artery Disease p=0.76 Presented at ACC 2005

www. Clinical trial results.org TNT Trial p<0.001 Presented at ACC 2005 Persistent elevations in liver aminotransferase levels, treatment-related adverse events, and study drug discontinuation due to adverse events were all higher in the high-dose group compared to the low-dose group. p<0.001

www. Clinical trial results.org TNT Trial: Summary Among patients with stable coronary heart disease treatment with high-dose atorvastatin to achieve an LDL below 100 mg/dL was associated with a reduction in the primary composite endpoint of major cardiovascular events at 5 years compared with treatment with low- dose atorvastatin to achieve an LDL of approximately 100 mg/dL. Among patients with stable coronary heart disease treatment with high-dose atorvastatin to achieve an LDL below 100 mg/dL was associated with a reduction in the primary composite endpoint of major cardiovascular events at 5 years compared with treatment with low- dose atorvastatin to achieve an LDL of approximately 100 mg/dL. There was no difference in all-cause mortality in the high-dose compared to the low-dose group. There was no difference in all-cause mortality in the high-dose compared to the low-dose group. Persistent elevations in liver aminotransferase, treatment-related adverse events, and study drug discontinuation all occurred more frequently in the high-dose atorvastatin group compared to the low- dose group. There was no difference by treatment group in persistent CK elevations, myalgia, or rhabdomyolysis. Persistent elevations in liver aminotransferase, treatment-related adverse events, and study drug discontinuation all occurred more frequently in the high-dose atorvastatin group compared to the low- dose group. There was no difference by treatment group in persistent CK elevations, myalgia, or rhabdomyolysis. Presented at ACC 2005

www. Clinical trial results.org TNT Trial: Summary cont’d The overall safety profile was consistent with other large atorvastatin trials, and was likely relatively low due to the exclusion of the 131 patients with abnormal liver-function tests or myalgia during the run-in phase. Despite the exclusion of these patients, persistent with abnormal liver-function tests were more frequent with the 80 mg atorvastatin group, suggesting close monitoring is warranted in pateints treated with this dose.The overall safety profile was consistent with other large atorvastatin trials, and was likely relatively low due to the exclusion of the 131 patients with abnormal liver-function tests or myalgia during the run-in phase. Despite the exclusion of these patients, persistent with abnormal liver-function tests were more frequent with the 80 mg atorvastatin group, suggesting close monitoring is warranted in pateints treated with this dose. In the PROVE-IT / TIMI 22 trial, aggressive lipid lowering with atorvastatin 80 mg was associated with a reduction in cardiovascular events compared with standard LDL lowering with pravastatin in patients with acute coronary syndrome.In the PROVE-IT / TIMI 22 trial, aggressive lipid lowering with atorvastatin 80 mg was associated with a reduction in cardiovascular events compared with standard LDL lowering with pravastatin in patients with acute coronary syndrome. The results from TNT confirm what was observed in PROVE-IT / TIMI 22 and suggest that aggressive lipid lowering to LDL levels <75 mg/dL reduces cardiovascular events in patients with stable coronary artery disease.The results from TNT confirm what was observed in PROVE-IT / TIMI 22 and suggest that aggressive lipid lowering to LDL levels <75 mg/dL reduces cardiovascular events in patients with stable coronary artery disease. Presented at ACC 2005